article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

However, recent breakthroughs in AI, such as predictive modelling, clinical trial optimisation, and personalised medicine, have demonstrated its potential. We spoke with Aaron Smith, a mathematician-turned-machine learning scientist and the founder of Unlearn , a company leading the charge in applying AI to optimise clinical trial efficiency.

article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Of all the companies that have launched since the beginning of the last decade, the most advanced is Arvinas, which has with Pfizer filed an application for approval of vepdegestrant in people with ER-positive, HER2-negative breast cancer and mutations in the ESR1 gene. But hurdles remain.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ICH E6(R3) Implementation Starts Now: Are You Ready?

Advarra

What Pharma Sponsors Are Asking As sponsors prepare for ICH E6(R3), a few common questions have emerged: Where do we start? Many pharma companies are unsure how to begin aligning with the new expectations, especially around trial design and quality systems.

article thumbnail

The Current State of Biotransformation Science 2024

Metabolite Tales Blog

The paper gives a useful insight into the most commonly used in vitro MetID practices across 26 pharma companies, and crucially reveals how effective these systems are at predicting circulating human metabolites. Hypha’s clients range from small through to large pharma companies.

article thumbnail

Best CDMO Practices for Startups: Navigating the Complex World of Contract Development and Manufacturing

Drug Patent Watch

The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharma companies were the originators in only 28% of approvals[4].

article thumbnail

Tackling complex manufacturing challenges in modern drug development

Drug Target Review

“A big part of my role involves interacting with customers, learning from them on their challenges and providing solutions to expedite their path to clinical trials or commercialisation of their drug,” Galbraith explains. Even large pharmaceutical companies often rely on CROs for their expertise and resources.

article thumbnail

The top biopharma conferences in 2025

BioPharma Drive: Drug Pricing

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.